How should thyrotoxicosis be managed in a pregnant woman with pre‑eclampsia?

Management of Thyrotoxicosis in Pregnant Women with Pre-eclampsia

Thyrotoxicosis in a pregnant woman with pre-eclampsia requires immediate antithyroid drug therapy to prevent life-threatening complications including thyroid storm, congestive heart failure, and fetal death, as inadequately treated maternal thyrotoxicosis significantly increases the risk of these severe outcomes when combined with pre-eclampsia.

Critical Understanding of the Combined Risk

The coexistence of thyrotoxicosis and pre-eclampsia creates a particularly dangerous clinical scenario. Inadequately treated maternal thyrotoxicosis is independently associated with increased risk of pre-eclampsia, congestive heart failure, medically indicated preterm delivery, intrauterine growth restriction, and fetal death 1. When pre-eclampsia is already present, the risk of cardiovascular complications and thyroid storm escalates dramatically 2, 3.

Pre-eclampsia itself can precipitate thyrotoxic crisis 3, 4, making aggressive management of the thyroid disorder essential. The hypermetabolic state of thyrotoxicosis combined with the cardiovascular stress of pre-eclampsia creates a perfect storm for maternal decompensation.

Immediate Diagnostic Steps

Measure the following urgently:

• TSH, free T4, total T3, and TRAb levels 1
• Interpret results using trimester-specific reference ranges (TSH is normally suppressed in first trimester)
• Distinguish true Graves' disease from gestational transient thyrotoxicosis
• Look for clinical signs: goiter with bruit/thrill, tachycardia disproportionate to pre-eclampsia, heat intolerance 1

Antithyroid Drug Selection Based on Gestational Age

First Trimester (≤16 weeks):

Use propylthiouracil (PTU) exclusively 1, 5. While PTU carries hepatotoxicity risk, methimazole (MMI) is associated with embryopathy including aplasia cutis and choanal/esophageal atresia during first trimester exposure.

Beyond 16 Weeks:

Either continue PTU or switch to methimazole through shared decision-making 5. The 2012 Endocrine Society guidelines recommend switching to MMI after first trimester due to PTU hepatotoxicity concerns 1, though recent evidence (2026) supports individualized continuation of PTU if well-tolerated 5.

Treatment Targets and Monitoring

• Use the lowest effective antithyroid drug dose to maintain maternal free T4 at or slightly above the upper limit of normal for pregnancy 1
• This approach minimizes fetal drug exposure while preventing maternal complications
• Monitor thyroid function every 2-4 weeks during active treatment
• Avoid overtreatment, which causes iatrogenic fetal hypothyroidism 1

Adjunctive Therapies

Beta-Blockers:

Metoprolol can be used for symptomatic control with obstetrical agreement 1. This is particularly important in pre-eclampsia where tachycardia and cardiovascular stress are already elevated. However, use cautiously as beta-blockers can affect placental/uterine function and cause neonatal hypoglycemia and bradycardia at high doses 3.

Fluid Management:

In the setting of pre-eclampsia with thyrotoxicosis, point-of-care ultrasound (POCUS) guidance for fluid management is invaluable 2. Serial LVOT VTI measurements help avoid both volume overload (risk of pulmonary edema) and inadequate perfusion, as static hemodynamic parameters are unreliable in this population.

Fetal Monitoring

If maternal TRAb levels are elevated (>3 times upper normal limit):

• Perform fetal ultrasound at 18-22 weeks and repeat every 4-6 weeks 1
• Look for signs of fetal thyroid dysfunction: goiter, growth restriction, tachycardia, hydrops, cardiac failure
• If fetal hyperthyroidism is diagnosed, treat with MMI or PTU with intensive monitoring 1

Delivery Considerations

Pre-eclampsia with thyrotoxicosis increases risk of medically indicated preterm delivery 1, 6. The stress of labor and delivery can precipitate thyroid storm 3. Ensure:

• Adequate antithyroid drug coverage peripartum
• Beta-blockade for cardiovascular protection
• Multidisciplinary team (endocrinology, maternal-fetal medicine, anesthesia) present
• Avoid precipitating factors: infection, dehydration, excessive stress

Surgical Management

Thyroidectomy should be reserved only for patients with refractory hyperthyroidism or ATD contraindications 5, 7. If absolutely necessary, perform during second trimester when surgical risk is lowest. However, surgery carries increased risk of preterm labor and miscarriage 3, making it particularly hazardous when pre-eclampsia is present.

Common Pitfalls to Avoid

1. Undertreatment: Assuming mild thyrotoxicosis is acceptable—it is not when pre-eclampsia coexists, as both conditions synergistically increase cardiovascular risk
2. Overtreatment: Using excessive ATD doses that cause fetal hypothyroidism
3. Misdiagnosis: Failing to distinguish gestational transient thyrotoxicosis (which rarely needs treatment) from Graves' disease (which always requires treatment)
4. Ignoring TRAb: Not measuring TRAb levels, missing risk of fetal hyperthyroidism
5. Fluid mismanagement: Using standard fluid protocols without POCUS guidance in this high-risk population 2

Postpartum Management

Graves' disease commonly relapses postpartum 5. Continue monitoring and treatment. Methimazole is safe during lactation at low doses with no adverse effects on infant neurodevelopment 5. Radioactive iodine remains absolutely contraindicated during breastfeeding.